Journal article icon

Journal article

Improving delineation of true tumour volume with multimodal MRI in a rat model of brain metastasis

Abstract:

Purpose: Brain metastases are almost universally lethal with short median survival times. Despite this they are often potentially curable, with therapy failing only because of local relapse. One key reason relapse occurs is because treatment planning did not delineate metastasis margins sufficiently accurately, allowing residual tumour to regrow. The aim of this study was to determine the extent to which multimodal MRI, with a simple and automated analysis pipeline, could improve upon current clinical practice of single modality independent observer tumour delineation.

Methods and Materials: We used a single rat model of brain metastasis (ENU1564 breast carcinoma cells in BD-IX rats), with and without radiotherapy. Multimodal MRI data were acquired using sequences either in current clinical use or in clinical trial, and included post gadolinium T1-weighted images and maps of blood flow, blood volume, T1 and T2 relaxation times, and apparent diffusion coefficient.

Results: In all cases, independent observers underestimated the true size of metastases from single modality gadolinium-enhanced MRI (85±36µL vs. 131±40µL histological measurement), whilst multimodal MRI more accurately delineated tumour volume (132±41µL). Multimodal MRI offered increased sensitivity compared to independent observer for detecting metastasis (0.82 vs. 0.61, respectively), with only a slight decrease in specificity (0.86 vs. 0.98). Blood flow maps conferred the greatest improvements in margin detection for late-stage metastases after radiotherapy. Gadolinium-enhanced T1 weighted images conferred the greatest increase in accuracy of detection for smaller metastases.

Conclusions: These findings suggest that multimodal MRI of brain metastases could significantly improve the visualisation of brain metastasis margins, beyond current clinical practice, with the potential to decrease relapse rates and increase patient survival. This finding now needs validation in additional tumour models or clinical cohorts.

Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1016/j.ijrobp.2019.12.007

Authors

More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Sub department:
Oncology
Role:
Author
ORCID:
0000-0002-4169-8447
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Sub department:
Oncology
Role:
Author
ORCID:
0000-0001-5363-1699
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Sub department:
Oncology
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Sub department:
Oncology
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Oncology
Sub department:
Oncology
Role:
Author
ORCID:
0000-0002-5768-4429


Publisher:
Elsevier
Journal:
International Journal of Radiation Oncology - Biology - Physics More from this journal
Volume:
106
Issue:
5
Pages:
1028-1038
Publication date:
2020-01-13
Acceptance date:
2019-12-06
DOI:
ISSN:
0360-3016


Language:
English
Keywords:
Pubs id:
pubs:1078416
UUID:
uuid:e9384b53-dfd5-486e-b51c-8a1310fbc22d
Local pid:
pubs:1078416
Source identifiers:
1078416
Deposit date:
2019-12-19
ARK identifier:

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP